LY9 and plasma cell myeloma: Validating our strategy, we identified nearly all known canonical diagnostic markers and immunotherapeutic targets in myeloma, including BCMA, CD138/SDC1, CD38, CD56, SLAMF7/CS-1, CD46, Integrin-b7 (ITGB7), CD74/HLA-DR, TACI, CD48/ SLAMF2, and LY9/CD229.